Welcome to our dedicated page for Oscar Health SEC filings (Ticker: OSCR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Oscar Health, Inc. (NYSE: OSCR) SEC filings page on Stock Titan brings together the company’s regulatory disclosures from the U.S. Securities and Exchange Commission, with AI-powered tools to help interpret complex documents. Oscar identifies itself in these filings as a healthcare technology company whose Class A common stock trades on the New York Stock Exchange under the symbol OSCR. Through its reports, investors can review how the company structures its health insurance operations, technology initiatives, and capital markets activities.
Oscar’s annual reports on Form 10-K and quarterly reports on Form 10-Q provide overviews of its Individual & Family health plans, health technology solutions under the +Oscar brand, risk factors, and detailed financial statements. These core filings typically include information on revenues, medical costs, selling, general, and administrative expenses, membership metrics, and key non-GAAP measures such as Adjusted EBITDA, along with management’s discussion of business drivers.
The company’s current reports on Form 8-K offer more targeted updates. Recent 8-K filings describe quarterly financial results, reaffirmed guidance, and capital structure actions such as the issuance of 2.25% Convertible Senior Subordinated Notes due 2030, related capped call transactions, and an exchange agreement involving 7.25% Convertible Senior Notes due 2031. Other 8-Ks detail amendments to investment agreements, the planned termination of a revolving credit facility in connection with a notes offering, and changes to executive employment agreements and compensation structures.
Investors can also use this page to access information on convertible debt terms, events of default, subordination provisions, and potential share dilution from note conversion, all of which are described in Oscar’s indentures and related exhibits. Stock Titan’s AI summaries help explain the implications of these filings, highlight key sections of lengthy documents, and surface important items such as changes in guidance, financing transactions, and governance-related disclosures. This makes it easier to understand how Oscar’s regulatory filings relate to its health insurance operations, technology platform, and long-term financial strategy.
Oscar Health, Inc. disclosed an amendment to its January 27, 2022 Investment Agreement with Dragoneer-affiliated funds to permit an offering of securities. The filing states the company expects to terminate its revolving credit facility concurrently with the closing of the offering; that termination is contingent on the offering closing. The offering is described as a Rule 144A placement to qualified institutional buyers. A press release dated September 15, 2025 is attached as Exhibit 99.1 and the report is signed by Chief Financial Officer R. Scott Blackley.
Victoria Baltrus, identified as the issuer's Chief Accounting Officer, reported a transaction on 09/02/2025 involving Class A common stock of Oscar Health, Inc. (OSCR). The filing shows a Code F disposition on 09/02/2025 where 6,266 shares were withheld by the issuer to satisfy tax withholding at a reported price of $16.66 per share. After the transaction, Baltrus is reported to beneficially own 207,599 shares, which the filing states includes shares to be issued upon RSU vesting. The form was signed by an attorney-in-fact on 09/04/2025.
Oscar Health insider reported a disposition of Class A common stock by Richard Scott Blackley, the company's Chief Financial Officer and director. On 09/02/2025 the filing shows 28,166 shares of Class A common stock were disposed of under transaction code F at a price of $16.66 per share. After the reported transaction, Mr. Blackley beneficially owned 1,376,169 shares. The filing explains 28,166 shares were withheld by the issuer to satisfy tax withholding on vested restricted stock units and that the post-transaction holdings include shares to be issued upon RSU vesting. The Form 4 was signed by an attorney-in-fact on 09/04/2025.
Janet Liang, President of Oscar Insurance and a reporting person for Oscar Health, Inc. (OSCR), reported changes in her beneficial ownership on a Form 4. On 09/02/2025 she had 7,303 shares of Class A common stock disposed under transaction code F at a price of $16.66 per share; the filing explains these shares were withheld by the issuer to satisfy tax withholding arising from the vesting of restricted stock units (RSUs). After the reported transaction(s), Ms. Liang beneficially owns 179,865 shares of Class A common stock, which includes shares to be issued in connection with the vesting of one or more RSUs. The Form 4 is signed by an attorney-in-fact on 09/04/2025.
Oscar Health insider reporting: Adam McAnaney, the companys Chief Legal Officer, disposed of 1,845 shares of Class A common stock on 09/02/2025 at a reported price of $16.66 per share. After the transaction, he beneficially owns 181,093 shares, which includes shares to be issued upon vesting of restricted stock units (RSUs). The filing states the 1,845 shares were withheld by the issuer to satisfy tax withholding obligations related to RSU vesting rather than an open-market sale.
Mario Schlosser, President of Technology & CTO and a director of Oscar Health, reported a routine insider disposition on 09/02/2025. The filing shows 23,879 shares of Class A common stock were disposed of under code F at a price of $16.66 per share; the explanation states these shares were withheld by the issuer to satisfy tax withholding obligations upon the vesting of restricted stock units (RSUs). After the transaction, Schlosser beneficially owns 501,148 shares, a figure that the filer says includes shares to be issued on RSU vesting. The form is signed by an attorney-in-fact on 09/04/2025.
Oscar Health, Inc. plans to take part in the 2025 Wells Fargo Healthcare Conference on September 3, 2025, where it will reaffirm the updated full-year 2025 guidance it previously shared in its July 22, 2025 preliminary second-quarter results press release. This means the company is publicly standing by its current 2025 financial outlook when speaking with investors at the event.
The company also reminds readers that any statements about expected financial performance are forward-looking and subject to risks and uncertainties described in its recent annual and quarterly reports filed with the SEC.
Oscar Health, Inc. (OSCR) filed a Form 8-K on 22 Jul 2025 to notify investors that it has issued a press release containing preliminary second-quarter 2025 results and a revised full-year 2025 outlook. The press release is furnished as Exhibit 99.1 and, per the filing, is not deemed “filed” under Exchange Act Section 18. No quantitative metrics, guidance figures, or additional material events are included in the body of the 8-K. Other than furnishing the exhibit, the company reported no changes to previously disclosed risk factors, transactions, or governance matters.